text
"['\n1. 요약재무정보\n※ 당사의 연결 및 별도 재무제표는 K-IFRS에 따라 작성되었습니다.\n가. 요약 연결재무정보\n(단위 : 원)\n과 \xa0 \xa0 \xa0 \xa0 \xa0목\n제 11(당)기 3분기말\n제 10(전)기 기말\n제 9(전전)기 기말\n(2023년 9월말)\n(2022년 12월말)\n(2021년 12월말)\n[유동자산]\n575,501,446,510\n502,838,961,350\n530,997,632,140\n현금및현금성자산\n274,317,649,992\n264,577,929,433\n194,602,445,364\n매출채권\n101,081,550,371\n87,093,140,698\n87,062,715,587\n재고자산\n117,676,280,612\n100,145,707,910\n104,596,492,141\n기타\n82,425,965,535\n\xa051,022,183,309\n144,735,979,048\n[비유동자산]\n693,114,565,051\n654,885,972,254\n584,987,895,113\n유형자산\n450,780,090,232\n437,577,686,252\n414,803,475,803\n무형자산\n86,078,254,240\n61,982,966,596\n38,409,892,242\n투자부동산\n86,184,130,098\n83,677,564,292\n85,334,589,042\n기타\n70,072,090,481\n\xa071,647,755,114\n46,439,938,026\n자산총계\n1,268,616,011,561\n1,157,724,933,604\n1,115,985,527,253\n[유동부채]\n314,611,464,618\n182,707,624,179\n275,535,583,079\n[비유동부채]\n249,442,195,207\n284,906,306,588\n184,070,825,854\n부채총계\n564,053,659,825\n467,613,930,767\n459,606,408,933\n[자본금]\n43,074,825,000\n42,232,940,000\n42,231,625,000\n[주식발행초과금]\n286,677,842,726\n286,659,846,851\n286,641,753,496\n[자본조정]\n(10,418,809,505)\n(2,882,433,841)\n(735,579,921)\n[기타자본구성요소]\n142,724,408,364\n141,593,153,862\n147,854,386,598\n[이익잉여금]\n216,098,820,923\n203,973,266,419\n180,386,933,147\n[소수주주지분]\n26,405,264,228\n\xa0 \xa0 \xa018,534,229,546\n-\n자본총계\n704,562,351,736\n690,111,002,837\n656,379,118,320\n부채 및 자본총계\n1,268,616,011,561\n1,157,724,933,604\n1,115,985,527,253\n\u3000\n(2023.01.01 ~ 2023.09.30)\n(2022.01.01 ~ 2022.12.31)\n(2021.01.01 ~ 2021.12.31)\n매출\n482,918,565,825\n635,392,682,732\n593,227,915,741\n영업이익\n15,354,384,140\n16,672,741,081\n15,618,958,260\n당기순이익\n12,228,283,831\n12,771,293,993\n12,816,148,950\n지배회사지분손익\n17,981,867,852\n13,552,040,798\n12,816,148,950\n소수주주지분손익\n(5,753,584,021)\n(780,746,805)\n-\n기본주당이익\n1,439\n1,608\n1,519\n희석주당이익\n1,239\n1,458\n1,468\n연결에 포함된 회사수\n4\n5\n4\n주1) 2021년 3분기 중 당사의 동아참메드(주) 지분취득으로 연결대상 종속회사로 신규 편입되었으며, 2021년 4분기 중 Dong-A ST India Pvt., Ltd가 설립되어 당사의 연결대상 종속회사로 신규 편입되었습니다.주2) 2022년 4분기 중 당사의 Neurobo Pharmaceuticals, Inc 지분취득으로 연결대상 종속회사로 신규 편입되었습니다.\n나. 요약 별도재무정보\n(단위 : 원)\n과 \xa0 \xa0 \xa0 \xa0 \xa0목\n제 11(당)기 3분기말\n제 10(전)기 기말\n제 9(전전)기 기말\n(2023년 9월말)\n(2022년 12월말)\n(2021년 12월말)\n[유동자산]\n512,426,490,139\n452,307,482,539\n523,143,069,956\n현금및현금성자산\n230,653,328,565\n218,644,068,288\n189,992,928,310\n매출채권\n85,376,932,602\n86,354,697,004\n86,764,550,275\n재고자산\n103,581,410,901\n97,141,359,962\n101,871,834,753\n기타\n92,814,818,071\n\xa050,167,357,285\n144,513,756,618\n[비유동자산]\n722,895,195,893\n682,835,603,327\n592,139,107,102\n유형자산\n435,573,885,666\n432,956,853,589\n409,987,000,140\n무형자산\n73,415,946,837\n61,907,667,447\n38,311,041,156\n투자부동산\n86,184,130,098\n83,677,564,292\n85,334,589,042\n기타\n127,721,233,292\n104,293,517,999\n58,506,476,764\n자산총계\n1,235,321,686,032\n1,135,143,085,866\n1,115,282,177,058\n[유동부채]\n308,550,929,099\n178,432,421,098\n273,506,739,922\n[비유동부채]\n241,894,260,072\n284,746,306,588\n181,976,035,726\n부채총계\n550,445,189,171\n463,178,727,686\n455,482,775,648\n[자본금]\n43,074,825,000\n42,232,940,000\n42,231,625,000\n[주식발행초과금]\n286,677,842,726\n286,659,846,851\n286,641,753,496\n[자본조정]\n(10,418,809,505)\n(2,882,433,841)\n(735,579,921)\n[기타자본구성요소]\n144,255,019,764\n144,252,020,881\n148,842,963,745\n[이익잉여금]\n221,287,618,876\n201,701,984,289\n182,818,639,090\n자본총계\n684,876,496,861\n671,964,358,180\n659,799,401,410\n부채 및 자본총계\n1,235,321,686,032\n1,135,143,085,866\n1,115,282,177,058\n종속,관계,공동기업 투자주식의 평가방법\n원가법\n원가법\n원가법\n(2023.01.01 ~ 2023.09.30)\n(2022.01.01 ~ 2022.12.31)\n(2021.01.01 ~ 2021.12.31)\n매출\n439,517,337,779\n635,839,633,102\n590,123,656,392\n영업이익\n28,513,296,098\n30,527,351,413\n15,492,239,339\n당기순이익\n25,441,947,935\n9,019,750,289\n11,968,525,986\n기본주당이익\n2,994\n1,069\n1,418\n희석주당이익\n2,713\n996\n1,373\n']"
